{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:37:24Z","timestamp":1793039844644,"version":"4.5.0"},"reference-count":261,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bcp.2024.116270","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T22:44:59Z","timestamp":1715294699000},"page":"116270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Treatment of Epstein-Barr Virus infection in immunocompromised patients"],"prefix":"10.1016","volume":"225","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-3116","authenticated-orcid":false,"given":"Martyna","family":"Pociupany","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Snoeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Dierickx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-4896","authenticated-orcid":false,"given":"Graciela","family":"Andrei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2024.116270_b0005","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-Barr virus: Biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2024.116270_b0010","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-023-02187-9","article-title":"Epstein-Barr virus infection: the micro and macro worlds","volume":"20","author":"Huang","year":"2023","journal-title":"Virol. J."},{"key":"10.1016\/j.bcp.2024.116270_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CCO.0000000000000885","article-title":"Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: New insights in pathogenesis, classification and treatment","volume":"34","author":"Dierickx","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/v13122344","article-title":"Molecular basis of epstein\u2013barr virus latency establishment and lytic reactivation","volume":"13","author":"Murata","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2024.116270_b0025","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2020005466","article-title":"EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target","volume":"139","author":"Toner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2024.116270_b0030","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","article-title":"Latency and lytic replication in Epstein-Barr virus-associated oncogenesis","volume":"17","author":"M\u00fcnz","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.bcp.2024.116270_b0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/jclinpath-2019-205822","article-title":"Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors","volume":"72","author":"Kerr","year":"2019","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bcp.2024.116270_b0040","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-023-00708-5","article-title":"EBV Reactivation and Lymphomagenesis: More Questions than Answers","author":"Ford","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.bcp.2024.116270_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00081","article-title":"Viral-targeted strategies against EBV-associated lymphoproliferative diseases","volume":"9","author":"Hui","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00127","article-title":"Opportunities to target the life cycle of Epstein-Barr Virus (EBV) in EBV-associated lymphoproliferative disorders","volume":"9","author":"Dugan","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b0055","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24050997","article-title":"Novel therapeutics for Epstein-Barr virus","volume":"24","author":"Andrei","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2024.116270_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061479","article-title":"Oncogenic Properties of the EBV ZEBRA Protein","volume":"12","author":"Germini","year":"2020","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.bcp.2024.116270_b0065","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0271","article-title":"Epstein-Barr virus-associated lymphomas","volume":"372","author":"Shannon-Lowe","year":"2017","journal-title":"Philos. Trans. R. Soc., B"},{"key":"10.1016\/j.bcp.2024.116270_b0070","doi-asserted-by":"crossref","unstructured":"Y. Pei, A.E. Lewis, E.S. Robertson, Current progress in EBV-associated B-cell lymphomas, in: Adv Exp Med Biol, Springer New York LLC, 2017: pp. 57\u201374. https:\/\/doi.org\/10.1007\/978-981-10-5765-6_5.","DOI":"10.1007\/978-981-10-5765-6_5"},{"key":"10.1016\/j.bcp.2024.116270_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072133","article-title":"EBV and Lymphomagenesis","volume":"15","author":"Sausen","year":"2023","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.bcp.2024.116270_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-022-00404-3","article-title":"Burkitt lymphoma","volume":"8","author":"L\u00f3pez","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bcp.2024.116270_b0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00713","article-title":"The Global Landscape of EBV-Associated Tumors","volume":"9","author":"Shannon-Lowe","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090285","article-title":"Co-expression of the Epstein-Barr virus-encoded latent membrane proteins and the pathogenesis of classic Hodgkin lymphoma","volume":"10","author":"Vrzalikova","year":"2018","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.bcp.2024.116270_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/v15030714","article-title":"Epstein-Barr Virus History and Pathogenesis","volume":"15","author":"Yu","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2024.116270_b0100","doi-asserted-by":"crossref","unstructured":"L. Malpica, M.L. Marques-Piubelli, B.E. Beltran, J.C. Chavez, R.N. Miranda, J.J. Castillo, EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management, Am J Hematol 97 (2022) 951\u2013965. https:\/\/doi.org\/10.1002\/ajh.26579.","DOI":"10.1002\/ajh.26579"},{"key":"10.1016\/j.bcp.2024.116270_b0105","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): Risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.bcp.2024.116270_b0110","unstructured":"P.B. Doak, J.Z. Montgomerie, M.J. D K NORTHt DPHIL, F. Smith, F.J. MCPA Brit med, Reticulum Cell Sarcoma after Renal Homotransplantation and Azathioprine and Prednisone Therapy, 1952."},{"key":"10.1016\/j.bcp.2024.116270_b0115","doi-asserted-by":"crossref","unstructured":"T.E. Starzl, K.A. Porter, S. Iwatsuki, J.T. Rosenthal, B.W. Shaw, R.W. Atchison, M.A. Nalesnik, M. Ho, B.P. Griffith, T.R. Hakala, R.L. Hardesty, R. Jaffe, H.T. Bahnson, Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy, 1984.","DOI":"10.1016\/S0140-6736(84)90994-2"},{"key":"10.1016\/j.bcp.2024.116270_b0120","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2024.116270_b0125","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","article-title":"The tumor virus landscape of AIDS-related lymphomas","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2024.116270_b0130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ijlh.13863","article-title":"Plasmablastic lymphoma: An update","volume":"44","author":"Bailly","year":"2022","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.bcp.2024.116270_b0135","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/10428194.2021.1986218","article-title":"Plasmablastic lymphomas show restricted EBV latency profile and MYC gene aberrations","volume":"63","author":"Ramburan","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2024.116270_b0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030722","article-title":"Primary Effusion Lymphoma: A Clinicopathologic Perspective","volume":"14","author":"Gathers","year":"2022","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.bcp.2024.116270_b0145","article-title":"Primary Effusion Lymphoma: A Timely Review on the Association with HIV, HHV8, and EBV","volume":"12","author":"Liu","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.bcp.2024.116270_b0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pathol.2019.09.011","article-title":"Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach","volume":"52","author":"Hue","year":"2020","journal-title":"Pathology"},{"key":"10.1016\/j.bcp.2024.116270_b0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hon.2944","article-title":"Review on natural killer\/T-cell lymphoma","volume":"41","author":"He","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b0160","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1038\/onc.2012.529","article-title":"The PGC-1\/ERR signaling axis in cancer","volume":"32","author":"Deblois","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2024.116270_b0165","unstructured":"J. Feng, Q. Chen, P. Zhang, & X. Huang, W. Xie, H. Zhang, P. Yao, Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1\u03b2 Signaling Pathway, (2015). https:\/\/doi.org\/10.1007\/s12015-020-10112-8\/Published."},{"key":"10.1016\/j.bcp.2024.116270_b0170","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.3892\/or.2015.4305","article-title":"LMP1 promotes nasal NK\/T-cell lymphoma cell function by eIF4E via NF-\u03baB pathway","volume":"34","author":"Sun","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2024.116270_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214389","article-title":"Epstein-Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments","volume":"23","author":"Shechter","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116270_b0180","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734293","article-title":"Epstein-Barr Virus Epithelial Cancers\u2014A Comprehensive Understanding to Drive Novel Therapies","volume":"12","author":"Han","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116270_b0185","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1442-2042.2008.02030.x","article-title":"Infiltration of Epstein-Barr virus-harboring lymphocytes occurs in a large subset of bladder cancers","volume":"15","author":"Abe","year":"2008","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.bcp.2024.116270_b0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2017.10.005","article-title":"Association between Epstein-Barr virus (EBV) and cervical carcinoma: A meta-analysis","author":"de Lima","year":"2018","journal-title":"Gynecol Oncol 148"},{"key":"10.1016\/j.bcp.2024.116270_b0195","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1002\/jcp.27144","article-title":"Epstein-Barr virus and thyroid cancer: The role of viral expressed proteins","author":"Moghoofei","year":"2019","journal-title":"J Cell Physiol 234"},{"key":"10.1016\/j.bcp.2024.116270_b0200","first-page":"41","article-title":"Expression of Epstein-Barr virus in renal cell carcinoma","volume":"18","author":"Shimakage","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2024.116270_b0205","doi-asserted-by":"crossref","DOI":"10.1186\/s12894-022-00964-2","article-title":"Epstein-Barr virus infection is associated with the nuclear factor-kappa B p65 signaling pathway in renal cell carcinoma","volume":"22","author":"Farhadi","year":"2022","journal-title":"BMC Urol."},{"key":"10.1016\/j.bcp.2024.116270_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/v13050877","article-title":"Pathogenic role of epstein\u2013barr virus in lung cancers","volume":"13","author":"Becnel","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2024.116270_b0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07308-5","article-title":"Vasculogenic mimicry formation in EBV-associated epithelial malignancies","volume":"9","author":"Xiang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116270_b0220","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0270","article-title":"Epstein-Barr virus infection and nasopharyngeal carcinoma","volume":"372","author":"Tsao","year":"2017","journal-title":"Philos. Trans. R. Soc., B"},{"key":"10.1016\/j.bcp.2024.116270_b0225","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00432-021-03824-y","article-title":"Estimating the global burden of Epstein-Barr virus-related cancers","volume":"148","author":"Wong","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b0230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2024.116270_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008223","article-title":"Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma","volume":"16","author":"Zhu","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2024.116270_b0240","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.semcancer.2019.09.006","article-title":"Translational genomics of nasopharyngeal cancer","volume":"61","author":"Tsang","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2024.116270_b0245","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10120-021-01215-3","article-title":"Landscape of EBV-positive gastric cancer","volume":"24","author":"Saito","year":"2021","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.bcp.2024.116270_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114916","article-title":"Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation","volume":"164","author":"Tan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2024.116270_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060197","article-title":"Antiviral drugs for EBV","volume":"10","author":"Pagano","year":"2018","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.bcp.2024.116270_b0260","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/ilar\/ilv074","article-title":"Murine Models of Epstein-Barr Virus-Associated Lymphomagenesis","volume":"57","author":"Ahmed","year":"2016","journal-title":"ILAR J."},{"key":"10.1016\/j.bcp.2024.116270_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9020116","article-title":"Animal Models for Gammaherpesvirus Infections: Recent Development in the Analysis of Virus-Induced Pathogenesis","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.bcp.2024.116270_b0270","unstructured":"W.E. Crusio, H. Dong, H.H. Radeke, Antiviral Drug Discovery and Development, n.d. http:\/\/www.springer.com\/series\/5584."},{"key":"10.1016\/j.bcp.2024.116270_b0275","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1021\/bi801179f","article-title":"DNA polymerases as therapeutic targets","volume":"47","author":"Berdis","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2024.116270_b0280","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.3390\/v6114731","article-title":"KSHV targeted therapy: an update on inhibitors of viral lytic replication","volume":"6","author":"Coen","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2024.116270_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115322","article-title":"Acyclovir resistance in herpes simplex viruses: Prevalence and therapeutic alternatives","volume":"206","author":"Schalkwijk","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116270_b0290","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.clinthera.2018.07.006","article-title":"Antiviral Therapies for Herpesviruses: Current Agents and New Directions","volume":"40","author":"Poole","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bcp.2024.116270_b0295","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jpeds.2015.03.053","article-title":"Acyclovir Dosing and Acute Kidney Injury: Deviations and Direction","volume":"166","author":"Steinberg","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bcp.2024.116270_b0300","first-page":"116","article-title":"Monitoring the safety of antivirals. The example of the acyclovir experience","volume":"85","author":"Tilson","year":"1988","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcp.2024.116270_b0305","article-title":"Antiviral Drug Discovery and Development, Springer Singapore","author":"Crusio","year":"2021","journal-title":"Singapore"},{"key":"10.1016\/j.bcp.2024.116270_b0310","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1128\/AAC.44.10.2811-2815.2000","article-title":"Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients","volume":"44","author":"Pescovitz","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2024.116270_b0315","unstructured":"B.M. Colby, J.E. Shaw, G.B. Elion, J.S. Pagano\u2019, Effect of Acyclovir [9-(2-Hydroxyethoxymethyl)guanine] on Epstein-Barr Virus DNA Replication, 1980."},{"key":"10.1016\/j.bcp.2024.116270_b0320","doi-asserted-by":"crossref","first-page":"11857","DOI":"10.1128\/JVI.01005-09","article-title":"Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers","volume":"83","author":"Hoshino","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0325","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0022-3476(03)00192-6","article-title":"National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial","volume":"143","author":"Kimberlin","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bcp.2024.116270_b0330","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/00003495-199448030-00009","article-title":"Ganciclovir. An update of its therapeutic use in cytomegalovirus infection","volume":"48","author":"Markham","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.bcp.2024.116270_b0335","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, Valganciclovir for symptomatic congenital cytomegalovirus disease","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116270_b0340","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/j.1440-1746.2006.03257.x","article-title":"Ganciclovir and the treatment of Epstein-Barr virus hepatitis","volume":"21","author":"Adams","year":"2006","journal-title":"J. Gastroenterol. Hepatol. (Australia)"},{"key":"10.1016\/j.bcp.2024.116270_b0345","doi-asserted-by":"crossref","unstructured":"S. Bossolasco, K.I. Falk, M. Ponzoni, N. Ceserani, F. Crippa, A. Lazzarin, A. Linde, P. Cinque, Ganciclovir Is Associated with Low or Undetectable Epstein-Barr Virus DNA Load in Cerebrospinal Fluid of Patients with HIV-Related Primary Central Nervous System Lymphoma, 2006. https:\/\/academic.oup.com\/cid\/article\/42\/4\/e21\/386119.","DOI":"10.1086\/499956"},{"key":"10.1016\/j.bcp.2024.116270_b0350","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/infdis\/jix263","article-title":"Valganciclovir for the suppression of Epstein-Barr virus replication","volume":"216","author":"Yager","year":"2017","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2024.116270_b0355","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41390-019-0523-4","article-title":"Valganciclovir prophylaxis delays onset of EBV viremia in high-risk pediatric solid organ transplant recipients","volume":"87","author":"Albatati","year":"2020","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bcp.2024.116270_b0360","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1432-2277.2012.01485.x","article-title":"(Val-)Ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation","volume":"25","author":"H\u00f6cker","year":"2012","journal-title":"Transpl. Int."},{"key":"10.1016\/j.bcp.2024.116270_b0365","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jcv.2014.01.005","article-title":"Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab","volume":"59","author":"Gill","year":"2014","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0370","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1038\/sj.onc.1206402","article-title":"Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies","volume":"22","author":"Abdulkarim","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2024.116270_b0375","unstructured":"R. Snoeck, G. Andrei, E. De Clercq, Cidofovir in the treatment of HPV-associated lesions., Verh K Acad Geneeskd Belg 63 (2001) 93\u2013120, discussion 120-2."},{"key":"10.1016\/j.bcp.2024.116270_b0380","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2024.116270_b0385","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/v2102213","article-title":"Synthesis and Early Development of Hexadecyloxypropyl-cidofovir: An Oral Antipoxvirus Nucleoside Phosphonate","volume":"2","author":"Hostetler","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2024.116270_b0390","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir against Replication of Herpesviruses In Vitro","volume":"49","author":"Williams-Aziz","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2024.116270_b0395","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jmv.21165","article-title":"Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir","volume":"80","author":"Yoshizaki","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0400","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/ijc.21096","article-title":"Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts","volume":"116","author":"Wakisaka","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2024.116270_b0405","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000055132","article-title":"Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement","volume":"24","author":"H\u00e4nel","year":"2001","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.bcp.2024.116270_b0410","doi-asserted-by":"crossref","unstructured":"P. Chrisp, S.P. Clissold, O. Ringden, DRUG EVALUATION Foscarnet A Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Use in Immunocompromised Patients with Cytomegalovirus Retinitis, 1991.","DOI":"10.2165\/00003495-199141010-00009"},{"key":"10.1016\/j.bcp.2024.116270_b0415","doi-asserted-by":"crossref","first-page":"25246","DOI":"10.1074\/jbc.M111.248864","article-title":"Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase","volume":"286","author":"Zahn","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116270_b0420","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0163-7258(89)90097-1","article-title":"Antiviral effects of phosphonoformate (PFA, foscarnet sodium)","volume":"40","author":"Oberg","year":"1989","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2024.116270_b0425","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bcp.2024.116270_b0430","article-title":"A case of Epstein-Barr virus acute retinal necrosis successfully treated with foscarnet","volume":"25","author":"Suzuki","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.bcp.2024.116270_b0435","article-title":"Effects of intraocular treatments for Epstein-Barr virus (EBV) retinitis: A case report","volume":"100","author":"Mushiga","year":"2021","journal-title":"Medicine (united States)"},{"key":"10.1016\/j.bcp.2024.116270_b0440","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000520408","article-title":"Successful Treatment of Epstein-Barr Virus-Induced Necrotizing Retinitis with Intravitreous Ganciclovir, Foscarnet, and Methotrexate","volume":"13","author":"Cho","year":"2022","journal-title":"Case Rep. Ophthalmol."},{"key":"10.1016\/j.bcp.2024.116270_b0445","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1128\/JVI.03338-12","article-title":"Activity and Mechanism of Action of HDVD, a Novel Pyrimidine Nucleoside Derivative with High Levels of Selectivity and Potency against Gammaherpesviruses","volume":"87","author":"Coen","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0450","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1128\/AAC.02825-14","article-title":"Antiherpesvirus activities of two novel 4\u2019-thiothymidine derivatives, KAY-2-41 and KAH-39-149, are dependent on viral and cellular thymidine kinases","volume":"58","author":"Coen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2024.116270_b0455","article-title":"Targeting the signaling in Epstein-Barr virus-associated diseases: mechanism, regulation, and clinical study","volume":"6","author":"Cao","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2024.116270_b0460","article-title":"Maribavir: Mechanism of action, clinical, and translational science","author":"Sun","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bcp.2024.116270_b0465","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1177\/00185787221101480","article-title":"Maribavir","volume":"58","author":"Levien","year":"2023","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.bcp.2024.116270_b0470","article-title":"Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients","author":"Chou","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2024.116270_b0475","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2024.116270_b0480","doi-asserted-by":"crossref","first-page":"12108","DOI":"10.1128\/JVI.01575-09","article-title":"Maribavir Inhibits Epstein-Barr Virus Transcription in Addition to Viral DNA Replication","volume":"83","author":"Wang","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0485","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.7150\/thno.26823","article-title":"EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers","volume":"8","author":"Jiang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2024.116270_b0490","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1073\/pnas.0910717107","article-title":"Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism","volume":"107","author":"Sun","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2024.116270_b0495","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00949-22","article-title":"Cryo-EM Structure and Functional Studies of EBNA1 Binding to the Family of Repeats and Dyad Symmetry Elements of Epstein-Barr Virus oriP","volume":"96","author":"Mei","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0500","doi-asserted-by":"crossref","unstructured":"X. Sun, S.C. Kenney, Hsp90 inhibitors: A potential treatment for latent EBV infection?, 2010. www.landesbioscience.com\/journals\/cc\/article\/11594.","DOI":"10.4161\/cc.9.9.11594"},{"key":"10.1016\/j.bcp.2024.116270_b0505","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1080\/10428194.2016.1213823","article-title":"Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood","volume":"58","author":"Shatzer","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2024.116270_b0510","article-title":"Discovery of selective inhibitors against ebna1 via high throughput in silico virtual screening","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116270_b0515","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1177\/1087057110379154","article-title":"Development of a high-throughput screen for inhibitors of Epstein-Barr virus EBNA1","volume":"15","author":"Thompson","year":"2010","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.bcp.2024.116270_b0520","article-title":"Targeting EBV-encoded products: Implications for drug development in EBV-associated diseases","author":"Lv","year":"2023","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0525","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.antiviral.2014.01.018","article-title":"Small molecule inhibition of Epstein-Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome","volume":"104","author":"Lee","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2024.116270_b0530","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s10822-016-9899-y","article-title":"Computational analysis of EBNA1 \u201cdruggability\u201d suggests novel insights for Epstein-Barr virus inhibitor design","volume":"30","author":"Gianti","year":"2016","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bcp.2024.116270_b0535","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1128\/JVI.01628-10","article-title":"Roscovitine Inhibits EBNA1 Serine 393 Phosphorylation, Nuclear Localization, Transcription, and Episome Maintenance","volume":"85","author":"Kang","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0540","article-title":"Roscovitine in cancer and other diseases","volume":"3","author":"Cicenas","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.bcp.2024.116270_b0545","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/1078-0432.CCR-08-2790","article-title":"Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma","volume":"15","author":"Hui","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116270_b0550","doi-asserted-by":"crossref","first-page":"10336","DOI":"10.1128\/JVI.00747-09","article-title":"Role for G-Quadruplex RNA Binding by Epstein-Barr Virus Nuclear Antigen 1 in DNA Replication and Metaphase Chromosome Attachment","volume":"83","author":"Norseen","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0555","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.virol.2015.05.018","article-title":"The AT-hook DNA binding ability of the Epstein Barr virus EBNA1 protein is necessary for the maintenance of viral genomes in latently infected cells","volume":"484","author":"Chakravorty","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2024.116270_b0560","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1128\/jvi.69.3.1944-1950.1995","article-title":"Contribution of conserved amino acids in mediating the interaction between EBNA2 and CBF1\/RBPJk","volume":"69","author":"Ling","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0565","doi-asserted-by":"crossref","unstructured":"C.J. Farrell, J.M. Lee, E.-C. Shin, M. Cebrat, P.A. Cole, S.D. Hayward, Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide, 2004. www.pnas.orgcgidoi10.1073pnas.0306482101.","DOI":"10.1073\/pnas.0306482101"},{"key":"10.1016\/j.bcp.2024.116270_b0570","doi-asserted-by":"crossref","first-page":"e0174136","DOI":"10.1371\/journal.pone.0174136","article-title":"EBV induces persistent NF-\u03baB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells","volume":"12","author":"Takada","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116270_b0575","doi-asserted-by":"crossref","unstructured":"N. Ricco, S.J. Kron, Statins in Cancer Prevention and Therapy., Cancers (Basel) 15 (2023). https:\/\/doi.org\/10.3390\/cancers15153948.","DOI":"10.3390\/cancers15153948"},{"key":"10.1016\/j.bcp.2024.116270_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110056","article-title":"Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis","volume":"37","author":"Dorsch","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2024.116270_b0585","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1073\/pnas.0305149101","article-title":"Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas","volume":"101","author":"Katano","year":"2004","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2024.116270_b0590","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/hmg\/ddt512","article-title":"Statin-induced changes in gene expression in EBV-transformed and native B-cells","volume":"23","author":"Bolotin","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bcp.2024.116270_b0595","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2012.05.003","article-title":"Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A","volume":"95","author":"Dargart","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2024.116270_b0600","unstructured":"S. Shayani, Dasatinib, a Multikinase Inhibitor: Therapy, Safety, and Appropriate Management of Adverse Events, n.d. http:\/\/journals.lww.com\/drug-monitoring."},{"key":"10.1016\/j.bcp.2024.116270_b0605","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/j.1432-1033.2004.04099.x","article-title":"Ribosomal protein L22 inhibits regulation of cellular activities by the Epstein-Barr virus small RNA EBER-1","volume":"271","author":"Elia","year":"2004","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bcp.2024.116270_b0610","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/viro.2002.1354","article-title":"In vivo effects of the Epstein-Barr virus small RNA EBER-1 on protein synthesis and cell growth regulation","volume":"297","author":"Laing","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2024.116270_b0615","unstructured":"E.R.G. Mammalian, The Epstein-Barr virus noncoding RNA EBER2 transactivates the UCHL1 deubiquitinase to accelerate cell growth, Cell Cycle Control Mechanisms 69120 (n.d.). https:\/\/doi.org\/10.1073\/pnas.2115508118\/-\/DCSupplemental."},{"key":"10.1016\/j.bcp.2024.116270_b0620","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/cas.13634","article-title":"Therapies based on targeting Epstein-Barr virus lytic replication for EBV-associated malignancies","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2024.116270_b0625","doi-asserted-by":"crossref","DOI":"10.4172\/2161-0444.1000384","article-title":"Agents and Approaches for Lytic Induction Therapy of Epstein-Barr Virus Associated Malignancies","volume":"6","author":"NovaliA","year":"2016","journal-title":"Med Chem (los Angeles)"},{"key":"10.1016\/j.bcp.2024.116270_b0630","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3390\/cancers12082142","article-title":"Lytic Induction Therapy against Epstein-Barr Virus-Associated Malignancies: Past, Present, and Future","volume":"12","author":"Yiu","year":"2020","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.bcp.2024.116270_b0635","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/ijc.24945","article-title":"Suberoylanilide hydroxamic acid induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death","volume":"126","author":"Hui","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2024.116270_b0640","doi-asserted-by":"crossref","first-page":"8762","DOI":"10.1158\/0008-5472.CAN-06-1006","article-title":"Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression","volume":"66","author":"Feng","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116270_b0645","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-12-0574","article-title":"Cytolytic virus activation therapy for Epstein-Barr virus-driventumors","volume":"18","author":"Wildeman","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116270_b0650","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/509296","article-title":"Advances in virus-directed therapeutics against Epstein-Barr virus-associated malignancies","volume":"2012","author":"Ghosh","year":"2012","journal-title":"Adv Virol"},{"key":"10.1016\/j.bcp.2024.116270_b0655","first-page":"93","article-title":"Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A","volume":"19","author":"Seo","year":"2008","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2024.116270_b0660","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.canlet.2006.03.022","article-title":"Lytic induction and apoptosis of Epstein-Barr virus-associated gastric cancer cell line with epigenetic modifiers and ganciclovir","volume":"247","author":"Jung","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2024.116270_b0665","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b0670","series-title":"In the Treatment of Peripheral and Cutaneous T-Cell Lymphoma: a Case Report","article-title":"Inhibitor of histone deacetylation, depsipeptide (FR901228)","author":"Piekarz","year":"2001"},{"key":"10.1016\/j.bcp.2024.116270_b0675","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF01309995","article-title":"Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation","volume":"81","author":"Anisimov\u00e1","year":"1984","journal-title":"Arch. Virol"},{"key":"10.1016\/j.bcp.2024.116270_b0680","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/bcmd.1998.0178","article-title":"Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma","volume":"24","author":"Mentzer","year":"1998","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/j.bcp.2024.116270_b0685","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","article-title":"A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies","volume":"109","author":"Perrine","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2024.116270_b0690","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2021.34","article-title":"Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment","author":"Shahid","year":"2021","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.bcp.2024.116270_b0695","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1128\/JVI.76.11.5612-5626.2002","article-title":"Protein Kinase C-Independent Activation of the Epstein-Barr Virus Lytic Cycle","volume":"76","author":"Gradoville","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0700","doi-asserted-by":"crossref","unstructured":"A.H. Davies, R.J.A. Grand, F.J. Evans, A.B. Rickinson1, Induction of Epstein-Barr Virus Lytic Cycle by Tumor-Promoting and Non-Tumor-Promoting Phorbol Esters Requires Active Protein Kinase C, 1991.","DOI":"10.1128\/jvi.65.12.6838-6844.1991"},{"key":"10.1016\/j.bcp.2024.116270_b0705","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1006\/viro.2001.0965","article-title":"12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-\u03baB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase","volume":"286","author":"Gao","year":"2001","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2024.116270_b0710","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1007\/s00253-022-12029-3","article-title":"The roles of DNA methylation on the promotor of the Epstein-Barr virus (EBV) gene and the genome in patients with EBV-associated diseases","volume":"106","author":"Zhang","year":"2022","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.bcp.2024.116270_b0715","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-021-01154-x","article-title":"DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application","volume":"13","author":"Hu","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bcp.2024.116270_b0720","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-125","article-title":"Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins","volume":"12","author":"Li","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2024.116270_b0725","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2014.00367","article-title":"Epstein-Barr virus-host cell interactions: An epigenetic dialog?","volume":"5","author":"Niller","year":"2014","journal-title":"Front. Genet."},{"key":"10.1016\/j.bcp.2024.116270_b0730","doi-asserted-by":"crossref","unstructured":"R.F. Ambinder, K.D. Robertson, Q. Tao, DNA methylation and the Epstein-Barr virus, 1999.","DOI":"10.1006\/scbi.1999.0137"},{"key":"10.1016\/j.bcp.2024.116270_b0735","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1038\/sj.onc.1205699","article-title":"5-Azacytidine and 5-aza-2\u2019-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy","volume":"21","author":"Christman","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2024.116270_b0740","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-3-642-54490-3_19","article-title":"5-Azacytidine\/5-Azacitidine","volume":"201","author":"M\u00fcller","year":"2014","journal-title":"Recent Results Cancer Res."},{"key":"10.1016\/j.bcp.2024.116270_b0745","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/JVI.78.4.1893-1902.2004","article-title":"Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas","volume":"78","author":"Feng","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0750","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1158\/1078-0432.CCR-12-0574","article-title":"Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors","volume":"18","author":"Wildeman","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116270_b0755","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1128\/JVI.02487-09","article-title":"The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production","volume":"84","author":"Meng","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0760","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semcancer.2014.01.002","article-title":"Regulation of the latent-lytic switch in Epstein-Barr virus","volume":"26","author":"Kenney","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bcp.2024.116270_b0765","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1128\/JVI.01197-10","article-title":"Transforming Growth Factor \u03b2-Induced Reactivation of Epstein-Barr Virus Involves Multiple Smad-Binding Elements Cooperatively Activating Expression of the Latent-Lytic Switch BZLF1 Gene","volume":"85","author":"Iempridee","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0770","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcv.2006.06.013","article-title":"Hypoxia can contribute to the induction of the Epstein-Barr virus (EBV) lytic cycle","volume":"37","author":"Jiang","year":"2006","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b0775","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021716","article-title":"The Fight against the Carcinogenic Epstein-Barr Virus: Gut Microbiota, Natural Medicines, and Beyond","volume":"24","author":"Eladwy","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2024.116270_b0780","doi-asserted-by":"crossref","first-page":"725","DOI":"10.12659\/MSM.890423","article-title":"Effect of high dose vitamin C on Epstein-Barr viral infection","volume":"20","author":"Mikirova","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.bcp.2024.116270_b0785","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1753-4887.2007.tb00298.x","article-title":"Update: Effects of Antioxidant and Non-Antioxidant Vitamin Supplementation on Immune Function","volume":"65","author":"Webb","year":"2008","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.bcp.2024.116270_b0790","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3109\/10428194.2012.739686","article-title":"Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo","volume":"54","author":"Shatzer","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2024.116270_b0795","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3892\/etm.2010.139","article-title":"Antiviral effects of dehydroascorbic acid","volume":"1","author":"Uozaki","year":"2010","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2024.116270_b0800","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/jcm.24.4.527-531.1986","article-title":"In vitro effect of ascorbic acid on infectivity of herpesviruses and paramyxoviruses","volume":"24","author":"White","year":"1986","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.bcp.2024.116270_b0805","first-page":"298","article-title":"Biological activities and corresponding SARs of andrographolide and its derivatives","volume":"13","author":"Zhou","year":"2013","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116270_b0810","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1055\/s-0030-1250659","article-title":"Stage of action of naturally occurring andrographolides and their semisynthetic analogues against herpes simplex virus type 1 in vitro","volume":"77","author":"Aromdee","year":"2011","journal-title":"Planta Med."},{"key":"10.1016\/j.bcp.2024.116270_b0815","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ejmech.2012.07.030","article-title":"Anti-HIV activity of semisynthetic derivatives of andrographolide and computational study of HIV-1 gp120 protein binding","volume":"56","author":"Uttekar","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116270_b0820","doi-asserted-by":"crossref","unstructured":"T.-P. Lin, S.-Y. Chen, P.-D. Duh, L.-K. Chang, Y.-N. Liu, Inhibition of the Epstein-Barr Virus Lytic Cycle by Andrographolide, 2018.","DOI":"10.1248\/bpb.31.2018"},{"key":"10.1016\/j.bcp.2024.116270_b0825","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27144666","article-title":"Andrographolide Inhibits Epstein-Barr Virus Lytic Reactivation in EBV-Positive Cancer Cell Lines through the Modulation of Epigenetic-Related Proteins","volume":"27","author":"Malat","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bcp.2024.116270_b0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051306","article-title":"Resveratrol Prevents EBV Transformation and Inhibits the Outgrowth of EBV-Immortalized Human B Cells","volume":"7","author":"Espinoza","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116270_b0835","doi-asserted-by":"crossref","unstructured":"H. Zhang, C. Li, S.-T. Kwok, Q.-W. Zhang, S.-W. Chan, A Review of the Pharmacological Effects of the Dried Root of Polygonum cuspidatum (Hu Zhang) and Its Constituents., Evid Based Complement Alternat Med 2013 (2013) 208349. https:\/\/doi.org\/10.1155\/2013\/208349.","DOI":"10.1155\/2013\/208349"},{"key":"10.1016\/j.bcp.2024.116270_b0840","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.antiviral.2012.09.003","article-title":"Resveratrol inhibits Epstein Barr Virus lytic cycle in Burkitt\u2019s lymphoma cells by affecting multiple molecular targets","volume":"96","author":"De Leo","year":"2012","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2024.116270_b0845","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/np400757k","article-title":"Potential antiviral lignans from the roots of saururus chinensis with activity against Epstein-Barr virus lytic replication","volume":"77","author":"Cui","year":"2014","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.bcp.2024.116270_b0850","doi-asserted-by":"crossref","first-page":"7431","DOI":"10.1074\/jbc.RA120.012645","article-title":"The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation","volume":"295","author":"Wang","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2024.116270_b0855","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.antiviral.2009.12.002","article-title":"Inhibition of the Epstein-Barr virus lytic cycle by moronic acid","volume":"85","author":"Chang","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2024.116270_b0860","doi-asserted-by":"crossref","unstructured":"J. Ito, F.R. Chang, H.K. Wang, Y.K. Park, M. Ikegaki, N. Kilgore, K.H. Lee, Anti-AIDS agents. 48.(1) Anti-HIV activity of moronic acid derivatives and the new melliferone-related triterpenoid isolated from Brazilian propolis., J Nat Prod 64 (2001) 1278\u201381. https:\/\/doi.org\/10.1021\/np010211x.","DOI":"10.1021\/np010211x"},{"key":"10.1016\/j.bcp.2024.116270_b0865","first-page":"72","article-title":"Anti-herpes simplex virus activity of moronic acid purified from Rhus javanica in vitro and in vivo","volume":"289","author":"Kurokawa","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2024.116270_b0870","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3892\/or.2017.5489","article-title":"Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism","volume":"37","author":"Wang","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2024.116270_b0875","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3892\/ijo.2016.3502","article-title":"Berberine induces mitochondrial apoptosis of EBV-transformed B cells through p53-mediated regulation of XAF1 and GADD45?","volume":"49","author":"Bin Park","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2020.103802","article-title":"Berberine and ginsenoside Rg3 act synergistically via the MAPK\/ERK pathway in nasopharyngeal carcinoma cells","volume":"66","author":"Zhou","year":"2020","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.bcp.2024.116270_b0885","doi-asserted-by":"crossref","unstructured":"C. Man Tsang, Y. Chun Cheung, V. Wai-Yan Lui, Y. Ling Yip, G. Zhang, V. Weitao Lin, K. Chat-Pan Cheung, Y. Feng, S. Wah Tsao, Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts, 2013. http:\/\/www.biomedcentral.com\/1471-2407\/13\/619.","DOI":"10.1186\/1471-2407-13-619"},{"key":"10.1016\/j.bcp.2024.116270_b0890","article-title":"Curcumin Inhibits Proliferation of Epstein-Barr Virus-Associated Human Nasopharyngeal Carcinoma Cells by Inhibiting EBV Nuclear Antigen 1 Expression","volume":"2019","author":"Liu","year":"2019","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.bcp.2024.116270_b0895","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/17425255.2017.1360279","article-title":"Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions","volume":"13","author":"Adiwidjaja","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2024.116270_b0900","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2021.10304","article-title":"Curcumin sensitizes Epstein\u2013Barr\u2013immortalized lymphoblastoid cell lines to inorganic arsenic toxicity","volume":"22","author":"Mart\u00ednez-Castillo","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bcp.2024.116270_b0905","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3727\/096504021X16135618512563","article-title":"(\u2212)-Epigallocatechin-3-Gallate Inhibits EBV Lytic Replication via Targeting LMP1-Mediated MAPK Signal Axes","volume":"28","author":"Li","year":"2020","journal-title":"Oncol. Res."},{"key":"10.1016\/j.bcp.2024.116270_b0910","first-page":"455","article-title":"The Development of Prophylactic and Therapeutic EBV Vaccines","volume":"391","author":"Smith","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.bcp.2024.116270_b0915","unstructured":"B. Damania, J.M. Pipas, DNA Tumor Viruses, n.d."},{"key":"10.1016\/j.bcp.2024.116270_b0920","doi-asserted-by":"crossref","DOI":"10.3390\/v14112372","article-title":"How EBV Infects: The Tropism and Underlying Molecular Mechanism for Viral Infection","volume":"14","author":"Bu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2024.116270_b0925","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.734471","article-title":"Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases","volume":"12","author":"Cui","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116270_b0930","doi-asserted-by":"crossref","unstructured":"J.I. Cohen, Vaccine development for Epstein-Barr virus, in: Adv Exp Med Biol, Springer New York LLC, 2018: pp. 477\u2013493. https:\/\/doi.org\/10.1007\/978-981-10-7230-7_22.","DOI":"10.1007\/978-981-10-7230-7_22"},{"key":"10.1016\/j.bcp.2024.116270_b0935","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00104","article-title":"Progress in EBV vaccines","volume":"9","author":"Van Zyl","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b0940","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1073\/pnas.77.5.2979","article-title":"Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen","volume":"77","author":"Hoffman","year":"1980","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2024.116270_b0945","year":"1970","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.bcp.2024.116270_b0950","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus particles in cultured lymphoblasts from burkitt\u2019s lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2024.116270_b0955","first-page":"171","article-title":"First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen","volume":"84","author":"Gu","year":"1995","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.bcp.2024.116270_b0960","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0264-410X(98)00248-5","article-title":"Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine","volume":"17","author":"Jackman","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.bcp.2024.116270_b0965","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bcp.2024.116270_b0970","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.bcp.2024.116270_b0975","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A phase i trial of Epstein-Barr virus Gp350 vaccine for children with chronic kidney disease awaiting transplantation","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2024.116270_b0980","article-title":"Immunization with epstein\u2013barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose ebv challenge","volume":"9","author":"Cui","year":"2021","journal-title":"Vaccines (basel)"},{"key":"10.1016\/j.bcp.2024.116270_b0985","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.chom.2023.09.011","article-title":"A gB nanoparticle vaccine elicits a protective neutralizing antibody response against EBV","volume":"31","author":"Sun","year":"2023","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bcp.2024.116270_b0990","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1126\/scitranslmed.abf3685","article-title":"A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice","volume":"14","author":"Wei","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2024.116270_b0995","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.05598-11","article-title":"A Virus-Like Particle-Based Epstein-Barr Virus Vaccine","volume":"85","author":"Ruiss","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b1000","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1128\/JVI.02533-12","article-title":"An Epstein-Barr Virus Mutant Produces Immunogenic Defective Particles Devoid of Viral DNA","volume":"87","author":"Pavlova","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b1005","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-015-0415-2","article-title":"A chimeric EBV gp350\/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice","volume":"13","author":"Ogembo","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2024.116270_b1010","doi-asserted-by":"crossref","unstructured":"E.M. Perez, J. Foley, T. Tison, R. Silva, J.G. Ogembo, Novel Epstein-Barr virus-like particles incorporating gH\/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice, 2017. www.impactjournals.com\/oncotarget\/.","DOI":"10.18632\/oncotarget.13770"},{"key":"10.1016\/j.bcp.2024.116270_b1015","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrclinonc.2012.111","article-title":"T-cell therapy in the treatment of post-transplant lymphoproliferative disease","volume":"9","author":"Bollard","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1020","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.01409-07","article-title":"Phase I Trial of a CD8 + T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis","volume":"82","author":"Elliott","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b1025","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","article-title":"A phase II study evaluating the safety and efficacy of an adenovirus-\u03b4LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma","volume":"23","author":"Chia","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1030","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2006.10.047","article-title":"VRC 201\/203 Study Team, Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-na\u00efve and vaccinia-immune individuals","volume":"25","author":"Parrino","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.bcp.2024.116270_b1035","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4 + - and CD8 + -T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma","volume":"78","author":"Taylor","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b1040","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2024.116270_b1045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867918","article-title":"Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective","volume":"13","author":"Escalante","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116270_b1050","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/jmv.1890270210","article-title":"Vero cell-expressed Epstein-Barr virus (EBV) gp350\/220 protects marmosets from EBV challenge","volume":"27","author":"Emini","year":"1989","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b1055","doi-asserted-by":"crossref","unstructured":"M.A. Epstein, A.J. Morgan, S. Finerty, B.J. Randle, J.K. Kirkwood, Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine., Nature 318 (n.d.) 287\u20139. https:\/\/doi.org\/10.1038\/318287a0.","DOI":"10.1038\/318287a0"},{"key":"10.1016\/j.bcp.2024.116270_b1060","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jmv.21102","article-title":"A new animal model for primary and persistent Epstein-Barr virus infection: human EBV-infected rabbit characteristics determined using sequential imaging and pathological analysis","volume":"80","author":"Takashima","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b1065","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.virusres.2010.07.026","article-title":"Lifelong persistent EBV infection of rabbits with EBER1-positive lymphocyte infiltration and mild sublethal hemophagocytosis","volume":"153","author":"Kanai","year":"2010","journal-title":"Virus Res."},{"key":"10.1016\/j.bcp.2024.116270_b1070","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/JVI.76.1.421-426.2002","article-title":"Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model","volume":"76","author":"Rivailler","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2024.116270_b1075","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1126\/science.276.5321.2030","article-title":"An animal model for acute and persistent Epstein-Barr virus infection","volume":"276","author":"Moghaddam","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bcp.2024.116270_b1080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1059133","article-title":"EBV-associated diseases: Current therapeutics and emerging technologies","volume":"13","author":"Chakravorty","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116270_b1085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities","volume":"55","author":"Al Hamed","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bcp.2024.116270_b1090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00062","article-title":"EBV viral loads in diagnosis, monitoring, and response assessment","volume":"9","author":"Kimura","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2024\/5598324","article-title":"Single-Center Outcomes of Epstein-Barr Virus DNAemia in Adult Solid Organ Transplant Recipients","volume":"2024","author":"Dong","year":"2024","journal-title":"J Transplant"},{"key":"10.1016\/j.bcp.2024.116270_b1100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/bjh.18763","article-title":"Post-transplant lymphoproliferative disorder: Update on treatment and novel therapies","volume":"201","author":"Atallah-Yunes","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2024.116270_b1105","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/00007890-200104270-00012","article-title":"Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients","volume":"71","author":"Tsai","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2024.116270_b1110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder","volume":"11","author":"Reshef","year":"2011","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.bcp.2024.116270_b1115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/TP.0b013e3181761659","article-title":"Prospective Study of Sequential Reduction in Immunosuppression, Interferon Alpha-2B, and Chemotherapy for Posttransplantation Lymphoproliferative Disorder","volume":"86","author":"Swinnen","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2024.116270_b1120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.12659\/AOT.914101","article-title":"Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience","volume":"24","author":"Zhu","year":"2019","journal-title":"Ann. Transplant."},{"key":"10.1016\/j.bcp.2024.116270_b1125","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/cid\/cit391","volume":"57","author":"Styczynski","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2024.116270_b1130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bmt.2016.19","article-title":"Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT","volume":"51","author":"Burns","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.bcp.2024.116270_b1135","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1080\/10428194.2018.1543877","article-title":"Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk","volume":"60","author":"Van Besien","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2024.116270_b1140","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2024.116270_b1145","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1158\/1078-0432.CCR-11-1429","article-title":"Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma","volume":"18","author":"Tsai","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116270_b1150","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.bbmt.2010.05.004","article-title":"Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias","volume":"16","author":"McIver","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.bcp.2024.116270_b1155","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/TP.0b013e3182664042","article-title":"Increased infection rate after preemptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem-cell transplantation","volume":"94","author":"Petropoulou","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.bcp.2024.116270_b1160","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.bcp.2024.116270_b1165","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.838817","article-title":"Treatment Advances in EBV Related Lymphoproliferative Diseases","volume":"12","author":"Lv","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1170","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1175","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"KEYNOTE-087, Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1180","doi-asserted-by":"crossref","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","article-title":"Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma","volume":"25","author":"Song","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2024.116270_b1185","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41375-019-0545-2","article-title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study","volume":"34","author":"Song","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2024.116270_b1190","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.bcp.2024.116270_b1195","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jcyt.2023.04.003","article-title":"Epstein-Barr virus\u2013associated cellular immunotherapy","volume":"25","author":"Zhang","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bcp.2024.116270_b1200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(95)91150-2","article-title":"Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation","volume":"345","author":"Rooney","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2024.116270_b1205","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2024.116270_b1210","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bcp.2024.116270_b1215","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2024.116270_b1220","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1225","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/505912","article-title":"A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo","volume":"194","author":"Haque","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2024.116270_b1230","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","article-title":"CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease","volume":"18","author":"Slabik","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.bcp.2024.116270_b1235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219611","article-title":"The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis","volume":"14","author":"Du","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2024.116270_b1240","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-020-01508-4","article-title":"Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma","volume":"15","author":"Aftab","year":"2020","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1245","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s10555-020-09925-3","article-title":"Gastric cancer: a comprehensive review of current and future treatment strategies","volume":"39","author":"Sexton","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bcp.2024.116270_b1250","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/ijc.34511","article-title":"Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort","volume":"153","author":"M\u00f6hring","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2024.116270_b1255","doi-asserted-by":"crossref","unstructured":"M. Sharifi, P. Farrokhi, A. Sadeghi, M. Sharifi, R. Riechelmann, A. Moghaddas, Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east, 2022.","DOI":"10.1101\/2021.01.26.21250550"},{"key":"10.1016\/j.bcp.2024.116270_b1260","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-08768-7","article-title":"Results of the observational prospective RealFLOT study","volume":"21","author":"Giommoni","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2024.116270_b1265","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116270_b1270","first-page":"E25398","article-title":"The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis","volume":"100","author":"Fei","year":"2021","journal-title":"Medicine (united States)"},{"key":"10.1016\/j.bcp.2024.116270_b1275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1079515","article-title":"Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma","volume":"13","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2024.116270_b1280","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdh027","article-title":"Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma","volume":"15","author":"Comoli","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1285","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1200\/JCO.2005.02.6195","article-title":"Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes","volume":"23","author":"Comoli","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1290","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/mt.2013.242","article-title":"Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and\/or locally recurrent nasopharyngeal carcinoma","volume":"22","author":"Chia","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcp.2024.116270_b1295","author":"Mahadeo","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2024.116270_b1300","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40291-023-00648-z","article-title":"Tabelecleucel: First Approval","volume":"27","author":"Keam","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.bcp.2024.116270_b1305","doi-asserted-by":"crossref","first-page":"10029","DOI":"10.1128\/JVI.02241-06","article-title":"Bortezomib Induces Apoptosis of Epstein-Barr Virus (EBV)-Transformed B Cells and Prolongs Survival of Mice Inoculated with EBV-Transformed B Cells","volume":"81","author":"Zou","year":"2007","journal-title":"J. Virol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224002533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224002533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T23:40:30Z","timestamp":1718840430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224002533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":261,"alternative-id":["S0006295224002533"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116270","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Epstein-Barr Virus infection in immunocompromised patients","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116270"}}